The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
Abstract Background Short-chain fatty acids (SCFAs) alteration have been reported in irritable bowel syndrome (IBS), but the results are conflicting. Our study aims to explore the alteration of SCFAs in patients with diarrhea-predominant IBS (IBS-D) and their potential role in the occurrence and dev...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12876-020-01212-3 |
id |
doaj-7bf760cf36ac40c197d55e45607e0433 |
---|---|
record_format |
Article |
spelling |
doaj-7bf760cf36ac40c197d55e45607e04332020-11-25T03:47:52ZengBMCBMC Gastroenterology1471-230X2020-03-012011810.1186/s12876-020-01212-3The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndromeZhenyi Tian0Xiaojun Zhuang1Mei Luo2Wei Yin3Lishou Xiong4Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityDepartment of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityDepartment of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen UniversityDepartment of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityAbstract Background Short-chain fatty acids (SCFAs) alteration have been reported in irritable bowel syndrome (IBS), but the results are conflicting. Our study aims to explore the alteration of SCFAs in patients with diarrhea-predominant IBS (IBS-D) and their potential role in the occurrence and development of IBS. Methods We recruited patients with IBS-D defined by Rome IV criteria and age-and-gender matched healthy controls (HCs). A headspace solid-phase microextraction gas chromatography–mass spectrometric (HS-SPME-GC-MS) method was developed for the analysis of acetic, propionic and butyric acid in feces and serum. Results Compared with HCs, the levels of the serum propionate (2.957 ± 0.157 vs 2.843 ± 0.098 mmol/L, P = 0.012) and butyrate (2.798 ± 0.126 vs 2.697 ± 0.077 mmol/L, P = 0.012) were significantly higher in IBS-D group. No significant differences were found among two groups with regard to the concentration of fecal acetate (4.953 ± 1.065 vs 4.774 ± 1.465 mg/g, P = 0.679), propionate (6.342 ± 1.005 vs 6.282 ± 1.077 mg/g, P = 0.868) and butyrate (2.984 ± 0.512 vs 3.071 ± 0.447 mg/g, P = 0.607). Conclusions Metabolites of gut microbiota, the propionic and butyric acid, are increased in patients with IBS-D in serum but not in feces. It suggests that propionic and butyric acid might be associated with the occurrence and development of IBS.http://link.springer.com/article/10.1186/s12876-020-01212-3Gut microbiotaDiarrhea-predominant IBSShort-chain fatty acids |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhenyi Tian Xiaojun Zhuang Mei Luo Wei Yin Lishou Xiong |
spellingShingle |
Zhenyi Tian Xiaojun Zhuang Mei Luo Wei Yin Lishou Xiong The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome BMC Gastroenterology Gut microbiota Diarrhea-predominant IBS Short-chain fatty acids |
author_facet |
Zhenyi Tian Xiaojun Zhuang Mei Luo Wei Yin Lishou Xiong |
author_sort |
Zhenyi Tian |
title |
The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome |
title_short |
The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome |
title_full |
The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome |
title_fullStr |
The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome |
title_full_unstemmed |
The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome |
title_sort |
propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome |
publisher |
BMC |
series |
BMC Gastroenterology |
issn |
1471-230X |
publishDate |
2020-03-01 |
description |
Abstract Background Short-chain fatty acids (SCFAs) alteration have been reported in irritable bowel syndrome (IBS), but the results are conflicting. Our study aims to explore the alteration of SCFAs in patients with diarrhea-predominant IBS (IBS-D) and their potential role in the occurrence and development of IBS. Methods We recruited patients with IBS-D defined by Rome IV criteria and age-and-gender matched healthy controls (HCs). A headspace solid-phase microextraction gas chromatography–mass spectrometric (HS-SPME-GC-MS) method was developed for the analysis of acetic, propionic and butyric acid in feces and serum. Results Compared with HCs, the levels of the serum propionate (2.957 ± 0.157 vs 2.843 ± 0.098 mmol/L, P = 0.012) and butyrate (2.798 ± 0.126 vs 2.697 ± 0.077 mmol/L, P = 0.012) were significantly higher in IBS-D group. No significant differences were found among two groups with regard to the concentration of fecal acetate (4.953 ± 1.065 vs 4.774 ± 1.465 mg/g, P = 0.679), propionate (6.342 ± 1.005 vs 6.282 ± 1.077 mg/g, P = 0.868) and butyrate (2.984 ± 0.512 vs 3.071 ± 0.447 mg/g, P = 0.607). Conclusions Metabolites of gut microbiota, the propionic and butyric acid, are increased in patients with IBS-D in serum but not in feces. It suggests that propionic and butyric acid might be associated with the occurrence and development of IBS. |
topic |
Gut microbiota Diarrhea-predominant IBS Short-chain fatty acids |
url |
http://link.springer.com/article/10.1186/s12876-020-01212-3 |
work_keys_str_mv |
AT zhenyitian thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT xiaojunzhuang thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT meiluo thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT weiyin thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT lishouxiong thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT zhenyitian propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT xiaojunzhuang propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT meiluo propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT weiyin propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome AT lishouxiong propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome |
_version_ |
1724501591975788544 |